Plain-English translation of NCT04597294 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a new technique called hyperthermic intraperitoneal chemotherapy (HIPEC)—which delivers heated chemotherapy directly into the abdomen during surgery—can help prevent advanced stomach cancer from coming back. All participants will receive standard chemotherapy before and after surgery, but half will also receive the heated chemotherapy treatment during the operation. The trial will follow participants for 5 years to see if this combined approach works better than surgery and chemotherapy alone.
Advanced stomach cancer often returns inside the abdomen even after surgery and chemotherapy, which is why doctors are looking for ways to prevent this. This medication may be more effective when delivered directly to the area where cancer is most likely to return.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy infusions over several weeks before surgery, then undergo surgery (either with or without the heated abdominal treatment depending on which group you're assigned to), followed by more chemotherapy cycles after surgery. You would visit the hospital regularly for chemotherapy sessions and have imaging scans to monitor your progress. The trial involves follow-up visits at 6 months, 1 year, 3 years, and 5 years after surgery to track your health and watch for any cancer recurrence.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Poland